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RNA genesHepatocellular cancers (HCC) are highly resistant to chemotherapy. TGFb has been associated with
chemoresistance in some human cancers but the mechanisms involved are unknown. We explored
how TGFbmight contribute to altered responses to therapy by assessing the involvement and mech-
anistic contribution of extracellular vesicle long non-coding RNA (lncRNA) in mediating TGFb-
dependent chemoresistance. TGFb reduced the sensitivity of HCC cells to sorafenib or doxorubicin
and altered the release of both extracellular vesicles and of selected lncRNA within these vesicles.
Amongst these, lincRNA-ROR (linc-ROR), a stress-responsive lncRNA was highly expressed in HCC
cells and enriched within extracellular vesicles derived from tumor cells. Incubation with HCC-
derived extracellular vesicles increased linc-ROR expression and reduced chemotherapy-induced
cell death in recipient cells. Sorafenib increased linc-ROR expression in both tumor cells and extra-
cellular vesicles, whereas siRNA to linc-ROR increased chemotherapy-induced apoptosis and cyto-
toxicity. Tumor-initiating cells that express CD133 have an increased resistance to therapy. TGFb
increased expression of CD133+ cells and colony growth in limiting dilution assays, both of which
were attenuated by linc-ROR knockdown. These data provide mechanistic insights into primary che-
moresistance in HCC by showing that: (a) TGFb selectively enriches linc-RoR within extracellular ves-
icles, which has a potential role in intercellular signaling in response to TGFb; (b) expression and
enrichment of linc-ROR during chemotherapeutic stress plays a functional role in chemoresistance;
and (c) the effects of TGFb on chemoresistance in HCC may involve linc-RoR-dependent effects on
tumor-initiating cells. These ﬁndings implicate extracellular vesicle lncRNA as mediators of the che-
motherapeutic response, and support targeting linc-ROR to enhance chemosensitivity in HCC.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common can-
cer worldwide and the third most common cause of cancer mortal-
ity [1]. These cancers are highly chemoresistant. Although a large
number of therapeutic agents have been evaluated for the
treatment of HCC, most have been ineffective. Sorafenib and doxo-
rubicin are currently used for systemic or locoregional therapiesfor HCC but have limited efﬁcacy [2,3]. The heterogeneous nature
of HCC and the lack of targetable oncogenic driver mutations
further limit the effectiveness of targeted therapies. The poor prog-
nosis of unresectable HCC is related to the highly chemoresistant
nature of this cancer [4]. Understanding the mechanisms contrib-
uting to innate or acquired resistance to therapy in HCC is there-
fore necessary and essential in order to develop more effective
treatments.
Cellular toxicity and stress occurring during exposure to thera-
peutic agents such as sorafenib can elicit survival responses that
eventually result in resistance to these agents. Within the liver,
injury results in activation of mesenchymal cells with release of
soluble mediators such as transforming growth factor b (TGFb)
[5,6]. TGFb is a central contributor to hepatic ﬁbrosis and has been
implicated to contribute to hepatocarcinogenesis through diverse
mechanisms. TGF-b can modulate the expression of genes relevant
to tumor development and promote malignant transformation of
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Fig. 1. TGFb modulates chemosensitivity of HCC cells. (A) HepG2 or PLC/PRF-5 HCC cells (1  104/well) were cultured in 96 well collagen-coated plates for 24 h. Cells were
then exposed to diluent (controls), TGFb (10 ng/ml), doxorubicin (25 nM for HepG2 cells or 1.0 lM for PLC/PRF-5 cells) or sorafenib (2.5 lM). Cell proliferation was assessed
after 72 h using CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay. Proliferation index represents absorbance values expressed as a percentage of control cells. (B)
HepG2 cells were plated (1  104/well) in a 96 well plate and incubated with 0 or 10 ng/ml of TGFb for 24 h. Cells were then exposed to 1 or 2.5 lM sorafenib for 6 h. Caspase-
3/7 activity was assessed using a commercial luminometric assay. Data were expressed relative to luminescence values of 1 lM sorafenib without TGFb. Data represents the
means ± standard error of the mean (SEM) of 3 separate studies, with each study conducted in quadruplicate. ⁄p < 0.05.
K. Takahashi et al. / FEBS Open Bio 4 (2014) 458–467 459progenitor cells, and thereby link hepatic injury, ﬁbrotic responses
and cancer [7–10]. Although TGFb has been associated with che-
moresistance in human cancers [11], the mechanisms remain
unknown.
We postulated that TGFb enhances local environmental changes
and cellular reprogramming that facilitate chemoresistance. We
have recently shown that HCC cells can release extracellular vesi-
cles (EVs) such as exosomes [12]. These vesicles contain protein,
lipids and RNA derived from their donor cell cytoplasm and can
be taken up by other cells. The intercellular transfer of EV contents
thus provides a mechanism by which cells can communicate with
other cells in their local microenvironment. The presence of mRNAB C
0
20
40
60
80
100
120
0 1 10
Sorafenib
[ EV ], μg/ml
Vi
ab
le
 c
el
ls
, %
 o
f b
as
al
Doxoru
0
20
40
60
80
100
120
140
0 1
Vi
ab
le
 c
el
ls
, %
 o
f b
as
al
[ EV ], 
*
*#
A
Fig. 2. Tumor cell derived EV modulate chemosensitivity. (A) Analysis of extracellular
Nanosight N-300. The analysis revealed EVs with a mean size of 90 ± 40 nm. (B–D) HepG
medium and incubated with different concentrations of EVs. After 24 h, cells were expos
(D) camptothecin and cell viability was assessed after 48 h using an MTS assay. Bars exp
⁄p < 0.05, #p = 0.13.and non-coding RNA within EV is of particular interest because
these RNA molecules can modulate gene expression and cellular
activities in recipient cells [13–16]. Based on our previous ﬁndings
that HCC cell derived EVs contain miRNAs that can modulate trans-
formed cell behavior in target cells [12], we hypothesized that
intercellular signaling by EV RNA in response to TGFb could medi-
ate chemoresistance. Our studies evaluated the role of EV signaling
in tumor cell responses to TGFb and identiﬁed EV long non-coding
RNA signaling mediators involved in modulation of cellular
responses to chemotherapy. These ﬁndings provide several new
mechanistic insights into acquired chemoresistance in HCC, and
identify mediators and mechanisms that could be targeted toD Camptothecin
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Fig. 3. Effect of TGFb on lncRNA enrichment within EV. (A) Expression proﬁling of 90 lncRNAs was performed in donor HepG2 cells and EV derived from these cells after 72 h
incubation with 10 ng/ml of TGFb from three independent samples. Sixty-eight lncRNAs were identiﬁed in EVs of which thirteen lncRNAs were increased by >2-fold change in
EVs compared to their donor cells. Each column represents an independent lncRNA. (B) The expression of linc-ROR was assessed by qRT-PCR in HepG2 derived EVs following
incubation of donor cells with 0, 1 or 10 ng/ml TGFb for 72 h. Linc-ROR in EVs was expressed relative to expression in donor cells and normalized to that of RNU6B. Bars
represent the mean value ± SEM of 3 separate determinants. ⁄p < 0.05. (C) The Venn diagram summarizes the results of lncRNA proﬁling and illustrates number of lncRNA for
which the ratio was greater than 2-fold in each group. The central overlap indicates two lncRNA that were selectively enriched in all three proﬁling studies, and includes linc-
ROR and lincRNA-VLDLR.
Table 1
Effect of TGFb on EV long non coding-RNA released from HCC cells.
Basal expression TGFb, 10 ng/ml
lncRNA EV/cell ratio Log2 (fold change) lncRNA EV/cell ratio Log2 (fold change)
CAR Intergenic 10 4.39 HOTAIR 6.10
DISC2 (family) 3.99 lincRNA-VLDLR 4.86
DHFR ut (family) 3.81 CAR Intergenic 10 4.68
HAR1B 3.52 lincRNA-RoR 4.66
lincRNA-VLDLR 3.36 Tsix 3.04
Tsix 2.42 Y RNA-1 2.78
lincRNA-RoR 1.99 Nespas 2.66
lincRNA-p21 1.45 LUST 2.39
NEAT1 (family) 1.16 Jpx 2.31
SNHG4 2.29
Alpha 280 1.91
anti-NOS2A 1.79
Zfhx2as 1.16
Expression proﬁling of 90 lncRNAs was performed in HepG2 cells, and extracellular vesicles (EVs) derived from these cells under basal conditions or following incubation of
cells with TGFb 10 ng/ml for 24 h. LncRNAs increased by >2-fold are shown. Enrichment within EV of several lncRNA is noted, and amongst these, further enrichment of
lincRNA-RoR occurs in response to TGFb.
460 K. Takahashi et al. / FEBS Open Bio 4 (2014) 458–467enhance sensitivity and improve responses to conventional agents
that are used for the treatment of HCC.2. Materials and methods
2.1. Cell lines, culture, and reagents
HepG2 and PLC-PRF5 cells were obtained from American Type
Culture Collection (Manassas, VA), and cultured in DMEM high glu-
cose medium (HyClone Laboratories, Logan, UT), containing 10%
fetal bovine serum and 1% antibiotic–antimycotic (Invitrogen,
Grand Island, NY), at 37 C with 5% CO2. Non-malignant human
hepatocytes HH were obtained from Sciencell and cultured as
recommended by the supplier. For all studies with extracellular
vesicles, vesicle depleted medium was prepared by centrifuging
cell-culture medium at 100,000g overnight to spin down any
pre-existing vesicle content. Camptothecin and doxorubicin were
obtained from Sigma-Aldrich (St. Louis, MO), and sorafenib was
obtained from Selleck (Houston, TX). Compounds were dissolved
in 100% DMSO (Sigma–Aldrich, St. Louis, MO) and diluted with cul-
ture media to the desired concentration with a ﬁnal DMSO concen-
tration of 0.1%. DMSO 0.1% (v/v) was used as a solvent control.2.2. Isolation of EV
EV were isolated from HCC cells as previously described [17].
Cells (1  106) were plated in vesicle-depleted medium, and med-
iumwas collected after 3–4 days for EV isolation for EV isolation by
sequential centrifugation. Each isolation was veriﬁed using nano-
particle tracking analysis using a Nanosight N-300 (NanoSight
Ltd., Amesbury, UK) to determine size and quantity of EV isolated.
Isolated EVs were used immediately, or were resuspended in
50–100 ll of PBS and stored at 80 C.
2.3. RNA extraction and analysis
Total RNA was extracted from cells using Trizol (Invitrogen) or
from EV using ExoQuick-TC (System Biosciences, Mountain View,
CA). HepG2 cells (1  106) were plated in 11 ml of EV-depleted
medium on collagen-coated 10-cm dishes. After 3–4 days, the
medium was collected and sequentially centrifuged at 3000g
for 15 min to remove cells and cell debris. The supernatant was
transferred to a sterile vessel and combined with 2 ml ExoQuick-
TC. After an overnight precipitation at 4 C, total RNA was
extracted using SeraMir™ Exosome RNA Ampliﬁcation Kit (System
Biosciences, Mountain View, CA) according to the manufacturers’
Table 2
LncRNA expression proﬁling in malignant and non-malignant hepatocytes.
lncRNA HepG2/HH ratio Log2 (fold change)
anti-NOS2A 10.42
lincRNA-SFMBT2 9.58
lincRNA-RoR 5.42
Alpha 280 4.27
lincRNA-VLDLR 4.12
E2F4 antisense 4.10
HOXA3as 3.06
snaR 2.72
LUST 2.37
UM9-5 2.34
Zfhx2as 2.14
SNHG4 2.01
Gomafu 1.71
Zfas1 1.47
p53 mRNA 1.32
Air 1.29
SNHG5 1.10
H19 antisense 1.08
Hoxa11as 1.04
LOC285194 1.02
HAR1B 1.01
Expression proﬁling of selected lncRNAs was performed by comparing the
expression of genes in malignant human hepatocytes (HepG2 cells) and non-
malignant human hepatocytes (HH cells) using PCR. LncRNAs increased by >2-fold
in malignant cells compared to non-malignant cells are shown.
K. Takahashi et al. / FEBS Open Bio 4 (2014) 458–467 461instructions. RNA concentration was measured using NanoDrop
ND-2000 (Nano-Drop Technologies, Wilmington, DE).
2.4. Real-time PCR analysis
RNA was treated with RNase-free DNase I (Qiagen, Valencia,
CA). One microgram of RNA was reverse-transcribed to cDNA using
iScript cDNA Synthesis Kit (BIO-RAD Laboratories, Inc., Hercules,
CA), and Real-time quantitative RT-PCR (qRT-PCR) was performed
using a Mx3000p System (Stratagene, La Jolla, CA) to detect RNU6B
(U6) and lincRNA-ROR using SYBR green I (SYBR Advantage
qPCR Premix, Clontech., Mountain View, CA). The following PCR
primers were used: lincRNA-ROR primers, forward: 50-AGGAAG
CCTGAGAGTTGGC-30, reverse: 50- CTCAGTGGGGAAGACTCCAG-30,
U6, forward: 50-CTCGCTTCGGCAGCACA-30, reverse: 50-AACGCTTCA
CGAATTTGCGT-30.
2.5. Gene expression proﬁling
The expression of 90 lncRNA was performed using the LncPro-
ﬁler™ qPCR Array Kit (System Biosciences, Mountain View, CA).
RNA from EV or donor cells (n = 3 per each cell line) were treatedA B
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Fig. 4. Linc-ROR knockdown modulates chemotherapeutic response. (A–C) HepG2 cells w
siRNA (white bars). After 48 h, cells were plated (1  104/well) on 96 well plates and
concentrations. The number of viable cells was counted after 48 h using a hemocytom
determinants. ⁄p < 0.05.with DNase I and 2 lg of DNase-treated RNA was reverse tran-
scribed. Real-time PCR was performed (2X Maxima SYBR Green
with Rox, Fermentas, Glen Burnie, MD) and the cycle number at
which the reaction crossed a threshold (CT) was determined for
each gene. Raw CT values were normalized using a median CT
value (DCT = CTlncRNA  CTmedian). The relative amount of each
lncRNA in HCC cells relative to nonmalignant hepatocyte (fold
change) was described using the equation 2DDCT where
DDCT = DCTHCC cell  DCTnonmalignant hepatocytes and each lncRNA in
EVs relative to donor cells was described using the equation
2DDCT where DDCT =DCTEV  DCTdonor cell. The expression of 84
mRNAs associated with liver cancers was examined using RT2 Pro-
ﬁler™ PCR Array System (Qiagen, Valencia, CA). RNA was isolated
from cells and incubated with DNase I. One lg of DNase-treated
RNA was reverse transcribed using RT2 First Strand Kit (Qiagen,
Valencia, CA). Real-time PCR was performed (SABiosciences RT2
qPCR Master Mix, Qiagen, Valencia, CA) and mRNA expression
levels were evaluated using a comparative CT method.
2.6. Transfection of siRNAs
Two different siRNA against linc-RoR (50 to 30); siRNA linc-ROR-
1: GGAGAGGAAGCCTGAGAGT, and siRNA linc-ROR-2: GGTTAAAG
ACACA-GGGGAA as well as a non-targeting (NT) control siRNA
(siGENOME Non-Targeting siRNA) were purchased from Dharma-
con (Lafayette, CO). Validated siRNA to p53 siRNA were obtained
from Life Technologies (Grand Island, NY). Cell transfections were
performed using 50–100 nM siRNA using Lipofectamine 2000 (Life
Technologies, Grand Island, NY).
2.7. Luciferase assay
Cells were co-transfected with p53-Luc Plasmid (Agilent Tech-
nologies, Santa Clara, CA) and pRL-TK Renilla Vector (Promega,
Madison, WI) using Lipofectamine 2000 (Life Technologies, Grand
Island, NY). After 24 h, total cell extracts were assayed for lucifer-
ase activity using Dual-Luciferase Reporter Assay System (Pro-
mega), and a multiwell plate luminometer (Turner Biosystems,
Sunnyvale, CA) according to the manufacturer’s instruction.
2.8. Chemosensitivity assays
For studies of chemotherapeutic stress, cells were incubated
with varying concentrations of sorafenib, camptothecin, doxorubi-
cin or the appropriate diluent (DMSO) control for 72 h. Cells were
seeded (1  104/well) in collagen-coated 24-well or 96-well plates.
Cell viability was assessed by microscopy after staining with try-
pan blue and the number of viable cells expressed relative to cellC
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Fig. 5. Cellular effects of linc-ROR knockdown. (A–E) HepG2 cells were transfected with either siRNA to linc-ROR-1 or non-targeting control siRNA for 48 h. (A, B) Transfected
cells were incubated with 1 lM sorafenib, and analyzed 24 h later using an Accuri C6 ﬂow cytometer after staining with annexin V/propidium iodide. Cells in live, apoptosis
and necrosis group are expressed as percentages of the total cell population. (C) Transfected cells were plated (1  104/well) in a 96 well plate and incubated with diluent or
1 lM sorafenib for either 6 or 24 h. Caspase-3/7 activity was assessed using a commercial luminometric assay. Data were expressed relative to luminescence values of
controls without sorafenib. (D) Transfected cells were incubated with 10 lM sorafenib. After 24 h, cell cycle analysis was performed using Accuri C6 ﬂow cytometer after
staining with propidium iodide. Cells in sub G0/1, G1, S, and G2/M phases of the cell cycle are expressed as percentages of the total cell population. (E) Transfected cells were
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462 K. Takahashi et al. / FEBS Open Bio 4 (2014) 458–467counts at baseline. Inhibition of proliferation was assessed using a
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay Kit
MTS assay (Promega) and a FLUOstar Omega Microplate Reader
(BMG Labtech, Cary, NC). Proliferation index was expressed as a
percentage of absorbance values in experimental conditions com-
pared to that for control cells.
2.9. Caspase 3/7 activity assay
Cells were seeded (1  104/well) into 96-well collagen-coated
plates in appropriate media and incubated for 24 h. Then medium
was then replaced with medium containing different concentra-
tions of sorafenib. At selected time points, caspase-3/7 activitywas assessed using Caspase-GloR3/7 Assay kit (Promega, Madison,
WI) using a FLUOstar Omega Microplate Reader (BMG Labtech,
Cary NC). Data were expressed as relative luminescence values rel-
ative to those of controls without chemical substance.
2.10. Flow cytometry
Flow cytometry was performed using an Accuri C6 ﬂow cytom-
eter (Accuri, Ann Arbor, MI). For cell cycle analysis, cells were per-
meabilized with 70% ethanol, and DNA was stained with 20 lg/ml
propidium iodide, 0.2 mg/ml RNase A, and 0.01 mol/L PBS (pH 7.4).
Analysis was performed using FCS express version 3 software (De
Novo Software, Los Angeles, CA). For analysis of cell death, cells
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was examined by qRT-PCR after 24 or 48 h. (B) HepG2 cells were incubated with 1 lM sorafenib or diluent controls. After 24 h, EVs were isolated and EV linc-ROR expression
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recipient HepG2 cells. Expression of linc-ROR was normalized using the expression of RNU6B and expressed relative to controls. (D) HepG2 cells were transfected with either
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value ± SEM of 3 separate determinations. ⁄p < 0.05.
K. Takahashi et al. / FEBS Open Bio 4 (2014) 458–467 463were stained with annexin V-FITC or propidium iodide (Clontech,
Mountain View, CA), and the proportion of cells undergoing apop-
totic death was quantitated. For CD133+ and EpCAM expression,
cells were incubated with CD133/1 (AC133) pure mouse monoclo-
nal antibody (Miltenyi Biotec, Cambridge, MA), mouse monoclonal
(AUA1) antibody to EPCAM (Abcam, Cambridge, MA) or IgG1
(normal mouse IgG1 antibody, Santa Cruz, Dallas, Texas) as an
isotype control, and then with goat-anti-mouse IgG1-FITC (Santa
Cruz, Dallas, Texas).
2.11. In vitro limiting dilution assay
Self renewal capacity was assessed using spheroid formation
assays. Single cell suspensions were seeded (100 to 2000 / well)
in ultra-low attachment surface 96-well plates (Corning, Corning,
NY). Each well was supplemented with 100 ll of serum-free
DMEM medium or DMEM medium containing 1% FBS. The number
of spheroids was examined under a light microscope after 7 days.
The total number of wells containing spheroids was determined.
Twelve replicates were used for each condition and the percentage
of total cultures which yield positive spheroid (proportion) was
analyzed using L-Calc software (StemCell Technologies, Vancouver,
BC, Canada) based on Poisson distribution.
2.12. Statistical analysis
Data were expressed as the mean and standard error from at
least four replicates unless noted otherwise. Comparisons betweengroups were performed using the two-tailed Student’s t test, and
results were considered to be statistically signiﬁcant when
p < 0.05.3. Results
3.1. Does TGFb modulate chemotherapy resistance and increase EV
release?
Innate or acquired resistance to therapy is a hallmark of hepa-
tocellular cancers. In order to explore therapeutic strategies to
enhance chemotherapeutic responses, or to reduce the potential
for acquired resistance, we investigated the effects and mecha-
nisms by which TGFb could modulate responses of hepatocellular
cancer to therapy. Exogenous exposure of HepG2 or PLC-PRF5 cells
to TGFb did not signiﬁcantly alter the growth of either HepG2 or
PLC-PRF5 HCC cells. These cells were sensitive to sorafenib (IC50
of 2.8 lM in HepG2 cells and 2.4 lM in PLC-PRF5 cells) as well as
to doxorubicin (IC50 of 22 nM in HepG2 cells and 0.9 lM for
PLC-PRF5 cells). TGFb ameliorated growth inhibition with either
agent, with similar effects observed in both of the cell lines
(Fig. 1A). Furthermore, TGFb reduced sorafenib induced caspase
3/7 activity, consistent with a reduction in apoptosis (Fig. 1B).
Although TGFb has been reported to have divergent roles in can-
cers, these data are consistent with those from other malignancies
such as colorectal cancer, breast and ovarian cancers in which TGFb
has been implicated in chemoresistance [18].
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chemoresistance?
To ascertain if inter-cellular signaling by EV could modulate
responses to chemotherapy, we ﬁrst isolated EV from HepG2 cellsin culture and characterized them using electron microscopy, sed-
imentation characteristics and size quantitation using nanoparticle
tracking analysis using Nanosight (Fig. 2A). EV isolations consisted
of a homogeneously sized population of vesicles, many of which
have morphological features of exosomes. The term exosome refers
to a particular subset of vesicles that are deﬁned by their biogene-
sis, and therefore we have used the term EV rather than exosomes
in this report. The effect of exposure to tumor cell derived EV on
cell responses to chemotherapy was then ascertained. HepG2 cells
were cultured in EV-depleted medium in the presence or absence
of HepG2-derived EVs for 24 h. Cells were then incubated with
sorafenib, doxorubicin or camptothecin and cell viability was
assessed after 48 h. Cell viability increased in an EV concentration
dependent manner, with effects more prominent for doxorubicin
and camptothecin than for sorafenib (Fig. 2B–D). These observa-
tions indicate that EV can modulate cellular stress in response to
chemotherapeutic agents and enhance viability.
3.3. Is the expression of long non-coding RNA altered by TGFb?
In recent studies, we identiﬁed enrichment of non-coding RNA
in EV released by HCC cells. Long non-coding RNAs (lncRNAs) are
being increasingly implicated in human cancers [19], but their
involvement in chemoresistance are unknown. To identify poten-
tial mediators of TGFb mediated chemosensitivity, we examined
the effect of TGFb on exosomal lncRNA content using qRT-PCR.
There were marked quantitative differences in several but not all
lncRNA between expression in HepG2 cells and in EV derived from
the same cells (Fig. 3 and Table 1). These data suggest that EV
release of lincRNA-ROR may have speciﬁc roles in malignant cells.
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VLDLR that were increased in malignant hepatocytes, selectively
enriched within EV with EV release further enhanced by TGFb.
Together, these observations support the presence of TGFb medi-
ated pathways for selective enrichment of these lncRNAs within
EV, and their potential involvement in inter-cellular signaling in
response to TGFb and as potential mediators of chemoresistance.
We focused our efforts on linc-ROR because the greatest quantita-
tive differences in EV release in response to TGFb were observed
with this lncRNA, and was also highly up-regulated in malignant
HepG2 cells compared with non-malignant human hepatocytes
(Table 2).
3.4. Does linc-ROR prevent chemotherapy-induced cell death?
To evaluate the potential end-target effects of linc-ROR in HCC
cells, we next examined the effect of linc-ROR knockdown using
siRNA on chemotherapeutic stress. Transfection of HepG2 cells
with 100 nM linc-ROR-1 siRNA and linc-ROR-2 siRNA constructs
reduced linc-ROR expression by 73 ± 17% and 70 ± 10% respectively
after 48 h, compared with non-targeting siRNA controls. We then
investigated the effect of linc-ROR knockdown and observed a sig-
niﬁcant concentration-dependent effect on cell viability in
response to sorafenib, camptothecin, or doxorubicin with siRNA
to linc-ROR-1 compared to controls (Fig. 4). Further studies
showed that siRNA to linc-ROR-1 increased the percentage of cells
undergoing early apoptosis from 11.8% to 25.2% compared with
non-targeting control siRNA during incubation with 1 lM sorafe-
nib. siRNA to linc-ROR-1 also increased the percentage of total
apoptotic cells (Fig. 5A, B). Furthermore, caspase-3/7 activity was
increased by 1.7–1.8-fold in cells transfected with siRNA to linc-
ROR-1 compared to controls in HepG2 cells that were incubated
with sorafenib 1 lM for 6 and 24 h (Fig. 5C). Thus, linc-ROR can
functionally modulate chemotherapy-induced apoptosis and cell
survival.
To identify mechanisms by which deregulated expression of
linc-ROR could contribute to tumor cell behavior, we next assessed
the effect of knock-down of linc-RoR using siRNA on the mRNA
expression of several genes related to liver cancer using PCR based
assays. Caspase 8 and GADD45B, genes related to apoptosis and
DNA damage, were increased in HepG2 cells transfected with siR-
NA to linc-ROR-1 compared with control siRNA (Supplementary
Table 2). Moreover siRNA to linc-ROR-1 did not signiﬁcantly alter
cell cycle progression following incubation with 10 lM of sorafe-
nib, with an increase in percentage of cells in subG0/1 phase from
4.12% to 4.33% with siRNA to linc-ROR-1 compared with control
(Fig. 5D). As linc-ROR was reported to inhibit cell apoptosis
through repression of p53 [18], we examined p53 promoter activ-
ity (Fig. 5E). siRNA to linc-RoR-1 signiﬁcantly increased p53 activ-
ity. Furthermore, siRNA to p53 increased cell viability of HepG2
cells during doxorubicin exposure (Fig. 5F). Altogether, these data
indicate that the effects of linc-ROR could be mediated through
p53 dependent signaling.
3.5. Does sorafenib increase linc-ROR expression and release within
EV?
To examine the potential that linc-ROR could contribute to
acquired chemoresistance, we examined the effect of chemother-
apy on linc-ROR expression. First, we identiﬁed that incubation
of HepG2 cells with sorafenib signiﬁcantly increased linc-ROR
expression compared with control cells (Fig. 6A). Moreover, sorafe-
nib also increased linc-ROR expression within EVs (Fig. 6B).
Together, these studies show that sorafenib increases linc-ROR
expression within HCC cells and also within EV released by these
cells. Linc-ROR expression was assessed by qRT-PCR in recipientHepG2 cells after incubation with varying concentrations of HepG2
derived EVs for 24 h, and noted to increase in a concentration-
dependent manner supporting transfer of linc-ROR to recipient
cells by EV (Fig. 6C). In addition, incubation with EVs derived from
linc-ROR knockdown HepG2 cells signiﬁcantly reduced recipient
cell viability during sorafenib exposure compared with EVs derived
from cells transfected with control siRNA (Fig. 6D) These data
showing a correlation between resistance to chemotherapy and
linc-ROR in EV’s are consistent with inter-cellular transfer of linc-
ROR similar to the inter-cellular transfer of microRNA by EV that
we have previously shown [12,17].3.6. Does linc-ROR enhance expression of tumor-initiating cells?
Tumor initiating cells with a stem-cell like phenotype may have
an increased resistance to therapy. We ﬁrst evaluated the effect of
TGFb using limiting dilution assays of self-renewal capacity. The
proportion of single cells forming spheroids was increased by TGFb
(Fig. 7). Linc-ROR has been shown to be involved in epigenetic
reprogramming in embryonic stem cells [20]. We therefore exam-
ined the effect of linc-ROR on spheroid formation, and observed a
reduction in spheroid formation with knockdown of linc-ROR using
siRNA (Fig. 7). In HCC, tumor initiating cells can be identiﬁed based
on expression of cell surface markers such as CD133+ [21,22]. TGFb
increased expression of CD133+ cells (Fig. 8). These data indicate
that TGFb can enhance the growth of tumor initiating cells
in vitro. We next examined the effect of linc-ROR on expression
of CD133 expressing subpopulation using siRNA to linc-ROR-1 or
NT controls. A decrease in CD133+ cells was noted with knock-
down of linc-ROR compared to controls (Fig. 8). Moreover, siRNA
to linc-ROR-1 attenuated the effects of TGFb on CD133+ expression
and colony formation. Thus, linc-ROR dependent expression of
tumor-initiating cells may contribute to the effects of TGFb on che-
moresistance in HCC.4. Discussion
The poor prognosis of advanced HCC is, in part, related to the
lack of effective therapeutic agents for unresectable cancers. The
only agent currently approved by the FDA is sorafenib, a multi-
kinase inhibitor that exerts antiangiogenic and anti-tumor effects
by blocking multiple growth factor pathways [23]. Modest survival
beneﬁts have been reported with sorafenib in two phase III ran-
domized trials in patients with advanced HCC [2,24]. The use of
this agent is associated with acquired chemoresistance which lim-
its further beneﬁt. Our ﬁndings are of importance in understanding
potential mechanisms of acquired therapeutic resistance by identi-
fying mediators and pathways by which exposure to chemother-
apy modulates the local environment to limit toxicity.
Several lncRNA have been implicated in human liver diseases. A
critical role for lncRNA in several diverse aspects of human disease
is emerging but their speciﬁc involvement in targetable processes
remains mostly unexplored. Linc-ROR is amongst the most signif-
icantly upregulated lncRNA in malignant hepatocytes. This lncRNA
has been recognized to contribute to epigenetic regulators
involved in pluripotency and lineage commitment [25]. Recent
studies reported that linc-ROR plays a role in promoting survival
in iPSCs and ESCs by preventing the activation of cellular stress
pathways [20]. Our study shows that survival effects can be med-
iated in tumor cells following exposure to chemotherapy. The
involvement of a long non-coding RNA in therapeutic responses
adds to the current literature on functional capabilities of these
non-coding RNA genes. The demonstration of a functional contri-
bution to a clinically important effect provides a justiﬁcation for
future efforts to therapeutically target the expression of this
466 K. Takahashi et al. / FEBS Open Bio 4 (2014) 458–467lncRNA, through strategies similar to those proposed for targeting
other non-coding RNAs [26].
Our studies have also identiﬁed a previously unrecognized role
of linc-ROR as a mediator of cell-to-cell communication through
the transfer of extracellular vesicles. This represents an important
mechanism by which stressed cells can signal to other cells within
the local microenvironment to orchestrate responses such as acti-
vation of survival pathways. These may then result in acquired
chemoresistance within tissues and contribute to loss of therapeu-
tic effect of agents such as sorafenib.
Accumulating evidence implicates cancer stem cells in cancer
resistance to therapy as well as cancer growth and spread [22].
Cancer stem cells or tumor initiating cells are thought to represent
the least sensitive cell subpopulation to chemotherapy [27]. Dereg-
ulated expression and activity of TGFb has been characterized in
liver cancer stem cells [28]. Targeting liver cancer stem cells is
therefore an attractive strategy to improve therapeutic responses
for liver cancers and other tumors.[21,29] In order to do this, an
understanding of the mechanisms by which liver cancer stem cells
can mediate chemoresistance is essential. Within the liver, stem
cells can be identiﬁed on the basis of expression of cell surface
markers such as CD133, CD90, CD44 and EpCAM [22,30,31].
CD133+ liver cancer stem cells have the capacity for self-renewal
and ability to differentiate, and have been identiﬁed to confer
resistance to chemotherapy. Tumors arising from these cells are
difﬁcult to treat and lethal [28]. An alternate mechanism contribut-
ing to a chemoresistant phenotype in poorly differentiated tumors
may involve the loss of tumor cell differentiation with acquisition
of epithelial mesenchymal transition. The involvement of TGFb on
this potential mechanism was not directly addressed in our study.
In conclusion, these ﬁndings provide several new mechanistic
insights into acquired chemoresistance in HCC. The role of EV sig-
naling in tumor cell responses to TGFb was evaluated and speciﬁc
EV lncRNA mediators such as linc-ROR that are involved in modu-
lation of cellular responses to chemotherapy were identiﬁed. Tar-
geting these inter-cellular signaling mechanisms and mediators
may be useful in enhancing sensitivity and improving responses
to conventional therapeutic agents that are used for the treatment
of HCC.
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